Danish DanCann Pharma’s goal is to improve the lives of patients through medical cannabis and cannabinoids. The company has signed an agreement with WEECO Pharma worth 40 million DKK earlier this year and expects to reach its commercial breakthrough in the near future. In order to finance the next step in its development, the company is now carrying out a rights issue of 28.5 million DKK.

See DanCann Pharma’s CEO Jeppe Krog Rasmussen present the company below.